Request Trial
court-istock-521811810-berezko
berezko / iStockphoto.com
26 September 2018Americas

AIPPI 2018: Eli Lilly talks IPRs and biosimilar litigation

The inter partes review (IPR) process has had a huge impact on biosimilar litigation, but it isn’t truly fulfilling its goal of being an alternative to district court litigation.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Americas
Merchant & Gould hires 13 attorneys to open new Boston office
6 January 2026   The new recruits from a boutique Boston firm enables Merchant to expand and strengthen its tech and life sciences offering in the innovation hub.
Americas
PTAB year in review: A shifting landscape and outlook for 2026
2 January 2026   With the unprecedented changes at the PTAB in 2025, what could the year ahead hold for the agency? Lawyers from Sterne Kessler explore.
Americas
5 ways the USPTO director is changing US innovation
24 December 2025   John Squires has rewired the country’s patents system since becoming USPTO director—but which changes are most impactful? Sarah Speight explores.


Editor's picks

Who are the world’s best in-house counsel? Final call for the leading corporate IP professionals
Europe
Who are the world’s best in-house counsel? Final call for the leading corporate IP professionals
8 January 2026

Editor's picks

Europe
Who are the world’s best in-house counsel? Final call for the leading corporate IP professionals
8 January 2026
Europe
Abbott appeals ‘baffling’ decision in glucose monitoring device feud
16 December 2025
Americas
Teva scrubs 200-plus Orange Book patents after FTC turns the screw
11 December 2025
Americas
US govt backs Hikma over ‘skinny label’ rules
9 December 2025
Big Pharma
The clinical trial dilemma: Navigating European practice
27 November 2025
Europe
Biotech cleared to make biosimilar of $6bn treatment after landmark ruling
25 November 2025

More features

Who are the world’s best in-house counsel? Final call for the leading corporate IP professionals
Arnold & Porter loses another regulatory partner to growing rival
CIPA’s outgoing president: UK rejoining the UPC needs ‘support from business’
Merchant & Gould hires 13 attorneys to open new Boston office
Novo Nordisk secures China win ahead of key patent expiration
Edwards v Meril: Inside the UPC’s landmark medtech showdown
Bird & Bird targets Nordic life sciences growth with regulatory hire
Key EU and UK regulatory changes to watch for in 2026